Details of Disease

General Information of Disease (ID: DISLR0DG)

Disease Name	Iron overload disease
Synonyms	iron overload disease; rare hereditary hemochromatosis
Disease Class	5C64: Mineral absorption/transport disorder
Definition	OBSOLETE. Rare hereditary hemochromatosis comprises the rare forms of hereditary hemochromatosis (HH), a group of diseases characterized by excessive tissue iron deposition. These rare forms are hemochromatosis type 2 (juvenile), type 3 (TFR2-related), and type 4 (ferroportin disease). Hemochromatosis type 1 (also called classic hemochromatosis) is not a rare disease.
Disease Hierarchy	DIS01GPL: Grass pollen hypersensitivity DISLR0DG: Iron overload disease
ICD Code	ICD-11 ICD-11: 5C64.10 ICD-10 ICD-10: E83.1, G23.0 Expand ICD-11 '5C64.10 Expand ICD-10 'E83.1; 'G23.0

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Deferasirox	DM6ETS0	Approved	NA	[1]
Deferiprone	DMS2M7O	Approved	Small molecular drug	[2]
Exjade	DMHPRWG	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RT001	DM5XZJY	Phase 3	NA	[4]
FBS-0701	DMR3952	Phase 2	Small molecular drug	[5]
Deferitrin	DMOTBX5	Phase 1/2	Small molecular drug	[6]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
NanoDTPA	DM34J38	Investigative	NA	[7]
XEN-600	DM1MMJ8	Investigative	NA	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	Deferasirox FDA Label
2	Deferiprone FDA Label
3	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
4	ClinicalTrials.gov (NCT03570931) A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy. U.S. National Institutes of Health.
5	ClinicalTrials.gov (NCT01186419) Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload. U.S. National Institutes of Health.
6	ClinicalTrials.gov (NCT00069862) Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia. U.S. National Institutes of Health.
7	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.